-+ 0.00%
-+ 0.00%
-+ 0.00%

NURIX THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN REGISTRATIONAL PHASE 3 DAYBREAK CLL-306 TRIAL OF BEXOBRUTIDEG IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Reuters·08/04/2026 05:00:01

Please log in to view news